| 0 (0%) | 12-08 14:47 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.56  |
1-year : | 1.71 |
| Resists | First : | 1.34 |
Second : | 1.47 |
| Pivot price | 1.3 |
|||
| Supports | First : | 1.13 |
Second : | 0.94 |
| MAs | MA(5) : | 1.23 |
MA(20) : | 1.31 |
| MA(100) : | 1.39 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 10.5 |
D(3) : | 14.5  |
| RSI | RSI(14): 33.8 |
|||
| 52-week | High : | 1.84 | Low : | 0.81 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PMVP ] has closed below the lower bollinger band by 3.1%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 4.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.31 - 1.32 | 1.32 - 1.33 |
| Low: | 1.16 - 1.17 | 1.17 - 1.18 |
| Close: | 1.18 - 1.19 | 1.19 - 1.2 |
Mon, 03 Nov 2025
PMV Pharmaceuticals Insider Stock Sellers Must Be Relieved As Market Cap Falls To US$75m - simplywall.st
Tue, 28 Oct 2025
Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Mon, 27 Oct 2025
OrbiMed Advisors sells PMV Pharma (PMVP) shares for $1.52 million - Investing.com
Wed, 10 Sep 2025
PMV Pharmaceuticals Reports Promising Phase 2 Trial Results - MSN
Wed, 10 Sep 2025
TD Cowen Maintains PMV Pharmaceuticals(PMVP.US) With Buy Rating - 富途牛牛
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 53 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 3.2 (%) |
| Held by Institutions | 70 (%) |
| Shares Short | 1,530 (K) |
| Shares Short P.Month | 1,530 (K) |
| EPS | -1.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.27 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.1 % |
| Return on Equity (ttm) | -51.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.72 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -73 (M) |
| Levered Free Cash Flow | -48 (M) |
| PE Ratio | -0.73 |
| PEG Ratio | 0 |
| Price to Book value | 0.5 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|